Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with
stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular
effects of intravenous GMI-1070 in the outpatient setting.